Bristol/Agios AML Drug Idhifa Fails In Phase III

IDHENTIFY Studied The IDH2 Inhibitor In Its Approved Indication

 
• By Mandy Jackson
microscope
Idhifa missed the overall survival endpoint in Phase III

More from Clinical Trials

More from R&D